The expanding options for front-line treatment in patients with newly diagnosed CML-Reference-Cited by-同舟云学术

The expanding options for front-line treatment in patients with newly diagnosed CML

Published:2012-11 Issue:2 Volume:84 Page:287-299
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Pinilla-Ibarz Javier,Flinn Ian

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference81 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia v.2.2012. Available at: nccn.org.

2. Chronic myelogenous leukemia: biology and therapy;Faderl;Ann Intern Med,1999

3. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia;Preudhomme;N Engl J Med,2010

4. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group;Hehlmann;Blood,1994

5. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis;Kantarjian;Cancer,2003

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring;Therapeutic Drug Monitoring;2017-06

2. Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand;Clinical Therapeutics;2014-04

3. Cross Resistance: Treatment and Modeling;Targeted Cancer Treatment in Silico;2013-11-15

4. Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia;Biomedicine & Pharmacotherapy;2013-03

5. Systematic review of dasatinib in chronic myeloid leukemia;OncoTargets and Therapy;2013-03